陈俊仁，籍贯中国台湾，研究员，博士生导师，太阳成集团tyc122cc入口北京协和医学院特聘教授，太阳成集团tyc122cc入口血液病医院信息与资源中心首席技术专家。2017年入选武汉市发改委“武汉‘光谷3551’人才计划”；2018年入选中央组织部“国家人才创新长期项目”。获得国家自然科学基金、国家重点研发计划、院校创新工程项目、天津市科技计划等项目资助。
     院校引进人才，2020年加入院校，曾在中国种子集团有限公司及中国中化集团任中心常务副主任职务。

长期从事将数据科学应用于血液系统疾病研究领域，从真实世界挖掘数据来回答临床问题，现已开展的研究主要围绕在血液系统疾病患者的全景医学数据开展科学研究。从血液病的诊断、治疗和预后等全维度，根据不同疾病亚型的发病特点和治疗模式，结合数据科学技术，解决多学科领域交叉的共性难题，促进数据科学与医学研究领域知识体系的融通发展。2022年至今以通讯作者身份在“Nature Computational Science”、“Nature Communications”、“American Journal of Hematology”、“Leukemia”、“blood”等国际权威杂志发表论文15篇。

1．Junren Chen#*, Yigeng Cao#*, Yahui Feng#, Saibing Qi,# Donglin Yang#, Yu Hu#, Aiming Pang#, Qiujin Shen, Jieya Luo, Xiaowen Gong, Rongli Zhang, Xiaolin Zhai, Xueqian Li, Wen Yan, Xianjing Zhang, Mengyun Chen, Mingming Niu, Jialin Wei, Chen Liang, Weihua Zhai, Ningning Zhao, Xueou Liu, Sichang Liu, Wangsong Zhai, Ruixin Li, Xianfeng Shao, Dong Zhang, Mingyang Wang, Pan Pan, Mingyue Xu, Wei Zhang, Yunqiang Xu, Xiaofan Zhu, Ye Guo, Hong Wang, Zhen Song, Robert Peter Gale, Mingzhe Han, Sizhou Feng, Erlie Jiang*. Autonomous artificial intelligence prescribing a drug to prevent severe acute graft-versus-host disease in HLA-haploidentical transplants. Nat Commun 16(1):8391. (IF=15.7)

2．Fang Dong#*, Sen Zhang#, Caiying Zhu#, Zining Yang#, Lisha Wang#, Yao Ma, Jiayi Lu, Xialin Li, Xiaofang Wang, Nini Wang, Shanshan Zhang, Miner Xie, Jinhong Wang, Xiaobing Zhang, Yawei Zheng, Shihui Ma, Hideo Ema, Hui Cheng, Sha Hao, Toshio Suda, Yu Lan, Bing Liu, Ping Zhu*, Junren Chen*, Tao Cheng*. Heterogeneity of high-potency multilineage hematopoietic stem cells and identification of "Super" transplantability. Blood 146(5):546-557. (IF=21.1)

3．Xiaowen Gong#, Xiaolin Zhai,# Qiujin Shen#, Robert Peter Gale, Junren Chen*. Challenges determining the best target duration of deep molecular response after which to attempt achieving therapy-free remission in chronic myeloid leukaemia. Leukemia 39(4):810-815. (IF=13.4)

4．Yahui Feng#, Saibing Qi#, Yu Hu#, Wen Yan#, Yanping Ji, Mingyang Wang, Xiaowen Gong, Qiujin Shen, Wei Zhang, Huilan Liu, Xianjing Zhang, Mengyun Chen, Erling Chen, Xiaolin Zhai, Yi He, Donglin Yang, Aiming Pang, Mingzhe Han, Robert Peter Gale, Zimin Sun*, Erlie Jiang*, Junren Chen*. New criteria for estimating numbers of CD34-positive cells in a graft needed for posttransplant bone marrow recovery. Leukemia. 2024 Dec;38(12):2735-2738. (IF=12.8)

5．Qiujin Shen#, Xiaowen Gong#, Yahui Feng#, Yu Hu#, Tiantian Wang,Wen Yan, Wei Zhang, Saibing Qi, Robert Peter Gale, Junren Chen*. Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways? Blood Rev 68:101226. (IF=6.9)

6．Junren Chen#*, Robert Peter Gale, Yu Hu, Wen Yan, Tiantian Wang, Wei Zhang. Measurable residual disease (MRD)-testing in haematological and solid cancers. Leukemia 38(6):1202-1212. (IF=12.8)

7．Yahui Feng#, Saibing Qi#, Xueou Liu#, Li Zhang#, Yu Hu, Qiujin Shen, Xiaowen Gong, Wei Zhang, Junxia Wang, Wen Yan, Tiantian Wang, Huijun Wang, Zhen Song, Xiaofan Zhu*, Robert Peter Gale, Junren Chen*. Have we been qualifying measurable residual disease correctly? Leukemia 37(11):2168-2172. (IF=11.4)

8．Junren Chen#*, Robert Peter Gale, Yahui Feng, Yu Hu, Saibing Qi, Xueou Liu, Huaiping Zhu, Xiaowen Gong, Wei Zhang, Huilan Liu, Zimin Sun*. Are haematopoietic stem cell transplants stem cell transplants, is there a threshold dose of CD34-positive cells and how many are needed for rapid posttransplant granulocyte recovery? Leukemia 37(10):1963-1968. (IF=11.4)

9．Yigeng Cao#, Xiaowen Gong#, Yahui Feng#, Mingyang Wang#, Yu Hu#, Huilan Liu#, Xueou Liu#, Saibing Qi#, Yanping Ji#, Fang Liu#, Huaiping Zhu, Wenwen Guo, Qiujin Shen, Rongli Zhang, Ningning Zhao, Weihua Zhai, Xiaoqiang Song, Xin Chen, Liangquan Geng, Xia Chen, Xuetong Zheng, Qiaoling Ma, Baolin Tang, Jialin Wei, Yong Huang, Yuanyuan Ren, Kaidi Song, Donglin Yang, Aiming Pang, Wen Yao, Yi He, Yue Shang, Xiang Wan, Wei Zhang, Song Zhang, Guangyu Sun, Sizhou Feng, Xiaofan Zhu, Mingzhe Han, Zhen Song, Ye Guo*, Zimin Sun*, Erlie Jiang*, Junren Chen*. The Composite Immune Risk Score predicts overall survival after allogeneic hematopoietic stem cell transplantation: A retrospective analysis of 1838 cases. Am J Hematol. 2023 Feb;98(2):309-321. (IF=13.265)

10．Xueou Liu#, Yigeng Cao#, Ye Guo#, Xiaowen Gong#, Yahui Feng#, Yao Wang#, Mingyang Wang, Mengxuan Cui, Wenwen Guo, Luyang Zhang, Ningning Zhao, Xiaoqiang Song, Xuetong Zheng, Xia Chen, Qiujin Shen, Song Zhang, Zhen Song, Linfeng Li, Sizhou Feng, Mingzhe Han, Xiaofan Zhu*, Erlie Jiang*, Junren Chen*. Dynamic forecasting of severe acute graft-versus-host disease after transplantation. Nat Comput Sci 2(3):153-159. (IF=11.3)